China’s Pricing Squeeze Hits Novo Nordisk’s GLP-1 Sales
Chinese biotech companies are aggressively entering the $80-billion global GLP-1 weight-loss drug market, challenging U.S. pharmaceutical leaders like Eli Lilly and Novo Nordisk. Driven by domestic pricing pressures and government ... Read More